Qyuns Therapeutics Co., Ltd. (2509.HK) Stock

About Qyuns Therapeutics Co., Ltd.

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand. In addition, the company develops QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin that is in Phase Ib clinical trial to treat moderate-to-severe asthma and chronic obstructive pulmonary disease; and QX004N, an IL-23p19 inhibitor, which is in Phase II clinical trial to treat psoriasis and Crohn's disease. The company also develops QX027N, an anti-TSLPxIL-13 bispecific antibody that targets AD and asthma indications; QX030N, a IL-23p19/TL1A clinical stage long-acting bispecific antibody for the treatment of inflammatory bowel diseases; QX031N, a clinical stage TSLP/IL-33 long-acting bispecific antibody for the treatment of chronic obstructive pulmonary disease and asthma; and QX035N, a bispecific antibody for the treatment of respiratory and dermatology diseases. Further, it manufactures and sells pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.

Qyuns Therapeutics Co., Ltd. (2509.HK) stock trades at $17.97 with a market capitalization of $4.01B. The stock is valued at a price-to-earnings (P/E) ratio of 10.96, price-to-book of 5.02, price-to-sales of 4.97. Over the past 52 weeks the stock has ranged between $13.21 and $36.50, and currently trades 50.8% below its 52-week high.

On profitability, Qyuns Therapeutics Co., Ltd. generates a return on equity (ROE) of 68.31% — well above the market average, a sign of a high-quality business, an operating margin of 58.48%, a net profit margin of 38.97%.

Official website: www.qyuns.net